Weekly Update: Telehealth Reversion, Obesity Platform Race
Today marks Day One of post-pandemic Medicare telehealth. With Congress failing to extend flexibilities through the weekend, health systems face immediate billing friction as originating site restrictions return for non-behavioral health services. Meanwhile, AstraZeneca’s $18.5 billion late-week bet on CSPC’s LiquidGel platform signals a strategic pivot: the competitive focus in obesity is shifting from weekly efficacy to monthly adherence.
The week begins with structural adjustment. Amgen’s exit from the Kyowa Kirin rocatinlimab partnership—despite positive Phase 3 data—illustrates the new bar for late-stage assets: clinical success alone is no longer sufficient without clear commercial differentiation from entrenched incumbents. Watch for similar “pruning” announcements this week as large-cap pharma protects margins in crowded autoimmune categories.
What To Watch This Week
📍 Telehealth “Day 1” Impact
Today marks the first full business day where Medicare originating site restrictions return for non-behavioral health services. Clinic intake teams should expect significant billing friction as the “home-as-originating-site” rule expires.
💉 Monthly Dosing Dominance
AstraZeneca’s Friday announcement shifts the competitive focus this week from “weekly efficacy” to “monthly adherence” via long-acting peptide platforms. The deal positions AZ to leapfrog the current weekly injection standard-of-care.
🏢 Large-Cap Discipline
Following Amgen’s exit from the Kyowa Kirin partnership on Friday, monitor other Big Pharma “pruning” announcements this week as companies protect margins in crowded autoimmune categories.
Top Stories
Operational Reality: Medicare Telehealth Reverts to Pre-Pandemic Rules
⚠️ Effective Today: Medicare Telehealth Reversion
What expired: Temporary telehealth flexibilities (extended through Jan 30, 2026)
What returns: Originating site restrictions for non-behavioral health services
Patient impact: Must be in rural area + qualified medical facility for most telehealth
Provider impact: PTs, OTs, SLPs, audiologists can no longer furnish Medicare telehealth
Behavioral health exception: Mental health services can still be delivered to home, with in-person visit requirements
What Happened: The temporary legislative extension for Medicare telehealth flexibilities officially expired over the weekend (January 30, 2026). Congress failed to pass the appropriations bill that would have extended flexibilities through December 2027, with the package stalled over unrelated DHS funding disputes.
Why It Matters: Starting this morning, the “home-as-originating-site” rule is effectively dead for most Medicare beneficiaries. Patients seeking non-behavioral telehealth must generally be in a rural area and at a qualified medical facility—a hospital, clinic, or skilled nursing facility—to receive reimbursed services. Audio-only telehealth for general medical care ends.
Operational Impact: Health systems should expect 15-20% volume compression in digital health offerings. Physical therapists, occupational therapists, speech-language pathologists, and audiologists can no longer furnish Medicare telehealth services. Hospitals may no longer bill for outpatient therapy, diabetes self-management training, and medical nutrition therapy services when furnished remotely to beneficiaries in their homes.
What’s Preserved: Behavioral health telehealth remains available in the home, though in-person visit requirements return (within 6 months of initial service, annually thereafter). FQHCs and RHCs can continue billing for non-behavioral telehealth through December 31, 2026. Monthly ESRD visits for home dialysis, acute stroke services, and mental health services retain broader geographic flexibility.
Legislative Status: The House passed a bill extending flexibilities through December 2027, but Senate action remains uncertain. Based on the October-November 2025 lapse, retroactive coverage is possible if Congress eventually acts—but providers should not count on it for billing purposes this week.
AstraZeneca Leans Into Obesity with $18.5B CSPC Platform Alliance
💰 Deal Structure: AstraZeneca-CSPC Pharmaceuticals
Upfront: $1.2 billion
Development/Regulatory Milestones: Up to $3.5 billion across 8 programs
Sales Milestones: Up to $13.8 billion
Total Potential Value: $18.5 billion (largest obesity deal to date)
Scope: 8 obesity/T2D programs, including SYH2082 (GLP-1/GIP agonist entering Phase I)
Key Asset: LiquidGel once-monthly dosing platform technology + AI-driven peptide discovery
Territory: AZ gets global rights ex-China; CSPC retains Greater China
Close Expected: Q2 2026
What Happened: On Friday, AstraZeneca signed the largest obesity deal in pharma history—a strategic collaboration with CSPC Pharmaceutical Group (Hong Kong: 1093) encompassing eight development programs in obesity and type 2 diabetes. The $1.2 billion upfront payment specifically targets CSPC’s proprietary LiquidGel technology, which enables once-monthly dosing of GLP-1-based therapies.
Strategic Rationale: AstraZeneca is paying platform value, not just asset value. By acquiring rights to LiquidGel across all eight programs—plus the ability to deploy the technology on internal candidates—AZ is betting that adherence optimization will determine obesity market leadership. Current weekly injectables see significant dropout; a monthly regimen could fundamentally change patient retention curves.
Pipeline Details: The most advanced asset, SYH2082, is a long-acting GLP-1R/GIPR dual agonist (same class as Eli Lilly’s Zepbound) entering Phase I in China. Three additional preclinical programs target different mechanisms. Four more programs will be developed from scratch using CSPC’s AI-driven peptide discovery and LiquidGel formulation.
Competitive Context: This deal outpaces GSK’s $12.5 billion Jiangsu Hengrui agreement (July 2025) and approaches the scale of Pfizer’s $10 billion+ Metsera acquisition. AstraZeneca already has oral elecoglipron and weekly injectables in its pipeline—the CSPC deal adds the monthly modality and accelerates the company’s timeline to compete with Novo Nordisk and Eli Lilly. The obesity market across major markets is forecast to exceed $170 billion by 2031.
Oncology & Rare Disease
Ultragenyx UX111 BLA Resubmission: Sanfilippo Gene Therapy Advances
Filing: Ultragenyx resubmitted its Biologics License Application for UX111 (rebisufligene etisparvovec), an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA). The resubmission follows a July 2025 Complete Response Letter citing CMC-related observations from manufacturing facility inspections.
Data Package: The resubmission contains longer-term clinical data—up to 8.5 years of follow-up—on neurologic benefit endpoints, CSF heparan sulfate biomarkers, and comprehensive responses to FDA’s CMC observations. FDA previously acknowledged that neurodevelopmental outcome data were robust with no clinical data concerns.
Timeline: FDA granted Priority Review in February 2025. A PDUFA action date is expected within 30 days of resubmission, with a decision anticipated Q3 2026. If approved, UX111 would be the first approved therapy for Sanfilippo syndrome type A—a fatal lysosomal storage disease with median life expectancy of 15 years and no current treatment.
Akeega mHSPC: CHMP Positive Opinion Solidifies J&J Prostate Lead
Regulatory: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended an indication extension for Akeega (niraparib/abiraterone acetate dual-action tablet) for metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations.
Clinical Basis: The recommendation rests on Phase 3 AMPLITUDE data from 696 patients with HRR gene-altered mHSPC. The study demonstrated clinically meaningful improvements in radiographic progression-free survival versus standard of care. AMPLITUDE is the first clinical trial specifically designed for mHSPC patients with known HRR gene alterations.
Strategic Position: J&J enters this week with a solidified lead in the BRCA-mutated prostate cancer space. The dual-action tablet combines a PARP inhibitor (niraparib) with an androgen biosynthesis inhibitor (abiraterone) in a single pill, offering convenience advantages over separate dosing regimens.
Clinical & Research Updates
NaviFUS Glioblastoma: Blood-Brain Barrier Opening Advances to Phase III Planning
Progress: Taiwanese researchers using NaviFUS neuronavigation-guided focused ultrasound have confirmed successful blood-brain barrier opening in recurrent glioblastoma patients without safety events. The system combines focused ultrasound with systemic microbubbles to transiently increase BBB permeability, enabling chemotherapy delivery to tumor sites.
Clinical Data: Phase II results in Taiwan showed a median progression-free survival of 11 months and 6-month PFS rate of 66.7% when NaviFUS was combined with bevacizumab. The only treatment-related adverse event was transient scalp heating (Grade 1). The company plans to initiate a Phase III trial in Taiwan and a clinical trial in the United States.
Mechanism: Unlike implanted devices (SonoCloud) or MRI-guided systems (ExAblate), NaviFUS uses neuronavigation guidance in an outpatient setting without stereotactic frames or MRI suites. The reversible BBB opening lasts approximately 24 hours before returning to baseline.
STC3141 Sepsis: Phase II Success Supports Phase III Planning
Results: The carbohydrate-based drug STC3141 met its primary endpoint in a Phase II clinical trial for sepsis, demonstrating significantly reduced SOFA scores (a standard measure of sepsis severity) at Day 7 versus placebo. The high-dose group showed particularly impressive results, with statistically significant and clinically meaningful improvements.
Mechanism: STC3141 is the first sepsis treatment program centered on rebuilding immune homeostasis. The drug counteracts harmful biological molecule release during sepsis and reverses organ damage by targeting the core cause—immune dysregulation—rather than providing only symptomatic support.
Next Steps: Developer Grand Pharmaceutical Group (Hong Kong: 0512) plans to pursue breakthrough therapeutic drug designation with China’s NMPA. Phase III trial protocols are expected to be shared later this week. Sepsis affects approximately 49 million patients worldwide annually, with mortality exceeding 20%—there are currently no approved disease-modifying therapies.
Corporate Developments
Amgen Returns Rocatinlimab Rights: Positive Data Not Enough
🔄 Partnership Termination: Amgen-Kyowa Kirin
Asset: Rocatinlimab (anti-OX40 antibody)
Indication: Moderate-to-severe atopic dermatitis
Original Agreement: License and Collaboration Agreement (June 1, 2021)
Termination Date: January 30, 2026
Reason: Strategic portfolio prioritization by Amgen
Kyowa Kirin Role: Regains full global rights, continues to approval; Amgen continues manufacturing
Regulatory Timeline: Submission planned H1 2026
What Happened: Amgen terminated its collaboration with Kyowa Kirin for rocatinlimab—an anti-OX40 monoclonal antibody for moderate-to-severe atopic dermatitis—despite positive Phase 3 data. Kyowa Kirin regains full global rights and will continue regulatory filings and commercialization. Amgen will continue manufacturing the drug.
The Data: Phase 3 ROCKET-IGNITE and ROCKET-HORIZON trials met all co-primary and key secondary endpoints, including U.S. regulatory submission requirements for skin clearance (rIGA 0/1). Long-term ROCKET-ASCEND extension data demonstrated durable efficacy and extended dosing potential. The trials enrolled nearly 1,500 adults.
Why Exit Despite Success?: This decision reflects the “raising of the bar” in autoimmune portfolios. Even positive Phase 3 data is insufficient if an asset lacks clear differentiation from market leaders—in this case, Regeneron/Sanofi’s Dupixent, which has established deep commercial infrastructure and brand recognition. Amgen’s exit signals a focus on assets with potential for clear market leadership rather than me-too positioning.
Kyowa Kirin’s Path Forward: The Japanese company expressed confidence in rocatinlimab’s differentiated OX40 mechanism—targeting pathogenic T-cells directly rather than downstream cytokines. Regulatory submission is planned for H1 2026, making it a potential first-in-class T-cell rebalancing therapy if approved.
Moderna-Recordati: PA Partnership for mRNA-3927
🤝 Commercialization Partnership: Moderna-Recordati
Asset: mRNA-3927 (investigational mRNA therapy)
Indication: Propionic acidemia (rare metabolic disorder)
Upfront to Moderna: $50 million
Near-term Milestones: Up to $110 million
Additional: Commercial milestones + tiered royalties
Structure: Moderna leads development/manufacturing; Recordati leads global commercialization
Data Readout: Expected by end of 2026
What Happened: Moderna and Recordati announced a strategic collaboration to advance mRNA-3927 through final clinical development and, upon approval, global commercialization. Recordati pays Moderna $50 million upfront plus up to $110 million in near-term development and regulatory milestones. Moderna retains development and manufacturing leadership; Recordati handles commercialization.
About mRNA-3927: The investigational therapy encodes two enzymes (PCCA and PCCB) that are deficient in propionic acidemia patients, aiming to restore propionyl-CoA carboxylase activity. A Phase I/II trial published in Nature (2024) showed 70% reduction in metabolic decompensation risk. The registrational study has reached target enrollment, with pivotal data expected by year-end 2026.
Strategic Logic: Moderna gains a commercialization partner with established rare metabolic disease infrastructure; Recordati gains access to potentially the first disease-modifying therapy for propionic acidemia, which affects 1 in 100,000-150,000 individuals with no current disease-modifying treatments. If approved, mRNA-3927 could establish Moderna’s platform in inborn errors of metabolism.
Policy & Global Markets
India MedTech: Research-Linked Incentive Framework Active
Context: India’s Research-Linked Incentive (RLI) scheme for pharmaceutical and medtech sectors—a Rs 5,000 crore ($600M) initiative—continues driving prototype-to-commercialization funding. The scheme, which rolled out in 2023, focuses on strengthening research infrastructure through Centres of Excellence at NIPERs and promoting industry-academia linkages.
Recent Activity: The Department of Pharmaceuticals opened applications in January 2026 for two sub-schemes under the Rs 500 crore “Scheme for Strengthening of Medical Device Industry”—one targeting import reduction through domestic component manufacturing, another supporting clinical evidence generation for Indian-made devices.
Strategic Significance: India aims to move from a low-value, high-volume pharmaceutical participant to a high-value, high-volume global player. The PLI and RLI schemes together represent the government’s bid to capture innovation-driven share of the global pharma market, targeting 5% global market share by 2030.
Today’s Calendar
SCOPE Summit (Feb 2-5): The 17th annual Summit for Clinical Ops Executives begins today at Rosen Shingle Creek in Orlando. Key themes include Generative AI in clinical trials, patient-centric trial design, and site engagement strategies. Over 4,500 attendees expected across 30 conference tracks.
Compliance: First full business day of reverted Medicare telehealth reimbursement rules. Health systems should have updated billing codes and patient communication in place.
Late Friday Earnings: Glenmark Pharmaceuticals reported Q3 FY26 net profit of Rs 403.21 crore, up 15.9% year-over-year. Revenue rose 15.1% to Rs 3,900 crore, driven by India Formulations (+22.1%) and North America (+24.2%).
Related BioMed Nexus Coverage
Telehealth & Digital Health
- Medicare Telehealth Flexibilities: What Expires, What Remains
- Digital Health Billing: Navigating Post-Pandemic Reimbursement
- Behavioral Health Exception: Telehealth Rules for Mental Health Services
Obesity & Metabolic
- GLP-1 Pipeline: Weekly vs. Monthly Dosing Competitive Dynamics
- AstraZeneca’s Metabolic Strategy: From Elecoglipron to CSPC
- China Licensing Wave: GSK, AstraZeneca, and the Innovation Export
Autoimmune & Inflammation
- OX40 Mechanism: Rocatinlimab, Amlitelimab, and T-Cell Targeting
- Atopic Dermatitis Market: Dupixent Dominance and Challenger Positioning
- Big Pharma Portfolio Pruning: When Positive Data Isn’t Enough
Frequently Asked Questions
What exactly changed with Medicare telehealth today?
The temporary flexibilities that allowed Medicare beneficiaries to receive telehealth services from their homes anywhere in the U.S. expired January 30, 2026. Starting January 31 (with today being the first full business day), patients must generally be in a rural area and at a qualified medical facility—hospital, clinic, skilled nursing facility—to receive reimbursed non-behavioral telehealth services.
Are there any exceptions to the telehealth reversion?
Yes. Behavioral/mental health telehealth can still be delivered to patients at home, though in-person visit requirements return (within 6 months of initial service, annually thereafter). Monthly ESRD visits for home dialysis, acute stroke services, and mental health services retain broader geographic flexibility. FQHCs and RHCs can continue billing for certain services through December 2026.
What is AstraZeneca getting for $18.5 billion from CSPC?
AstraZeneca is acquiring: (1) global rights (ex-China) to eight obesity/diabetes programs, including SYH2082, a GLP-1/GIP dual agonist entering Phase I; (2) CSPC’s LiquidGel platform technology enabling once-monthly dosing; (3) AI-driven peptide drug discovery capabilities; and (4) the right to deploy LiquidGel technology on AZ’s own internal candidates. The $18.5B is the total potential value including upfront, milestones, and royalties.
Why did Amgen exit the rocatinlimab partnership despite positive Phase 3 data?
Amgen cited “strategic portfolio prioritization.” The subtext: even Phase 3 success isn’t sufficient if an asset lacks clear differentiation from market leaders. In atopic dermatitis, Dupixent has established commercial dominance. Rocatinlimab’s OX40 mechanism is differentiated, but Amgen apparently concluded the path to market leadership was too uncertain to justify continued investment.
What is Sanfilippo syndrome and why is UX111 significant?
Sanfilippo syndrome type A (MPS IIIA) is a fatal lysosomal storage disease with no approved treatment. Children lose the ability to communicate, play, and move before dying, typically by age 15. UX111 is an AAV9 gene therapy designed to deliver a functional copy of the missing SGSH gene, potentially halting disease progression. If approved, it would be the first-ever therapy for this condition.
What is STC3141 and why is it notable for sepsis?
STC3141 is a carbohydrate-based drug that targets immune dysregulation—the root cause of sepsis—rather than providing only symptomatic support. It’s the first sepsis treatment program focused on rebuilding immune homeostasis. Phase II results showed significant SOFA score reductions. There are currently no approved disease-modifying therapies for sepsis, which kills over 10 million people annually.
What is the Moderna-Recordati deal structure?
This is a commercialization partnership, not a divestment. Recordati pays Moderna $50M upfront plus up to $110M in milestones, plus royalties. Moderna retains development and manufacturing leadership; Recordati handles global commercialization upon approval. Moderna keeps upside through milestones and royalties while gaining a partner with rare disease commercial expertise.
What is NaviFUS and how does it help glioblastoma treatment?
NaviFUS is a neuronavigation-guided focused ultrasound system that temporarily opens the blood-brain barrier to allow chemotherapy to reach brain tumors. Unlike implanted devices or MRI-guided systems, it works in an outpatient setting without stereotactic frames. Phase II data showed 11-month median PFS when combined with bevacizumab, with minimal adverse events.
Stay Ahead of the Market
The investors and executives reading this article at 6 AM will act on these insights before the market opens. The question is whether you’ll be among them—or reacting to moves others made first.
BioMed Nexus Daily — Free
Join 12,000+ healthcare professionals
The essential morning briefing for biotech, medtech, and pharma. Delivered before market open, every trading day.
- Market-moving news and overnight developments
- Key catalysts and earnings on deck
- Regulatory decisions and clinical data releases
No spam. Unsubscribe anytime. Read by analysts at Goldman, Morgan Stanley, and JP Morgan.
BioMed Nexus Pro — $395/year
For serious investors and industry operators
Institutional-grade analysis that gives you an edge. The same frameworks used by hedge funds and BD teams.
Everything in Free, plus:
- Full Weekday Pro Intelligence (Monday–Friday)
- 30-Day Catalyst Watch & Risk Outlook Matrix
- Tomorrow’s Top 5 Near-Term Catalysts Across Biotech & Medtech
- Trial Decoder, plain-English reads on key clinical data
- Money Flow Monday, financings, BD moves, and quiet deal activity
- Deal Heat Tracker with professional, institutional-grade analysis
Annual billing with a single invoice, easy to expense as a research or professional subscription.
“BioMed Nexus is the first thing I read every morning. It’s replaced three other newsletters.”
— Director of Business Development, Top 10 Pharma
BioMed Nexus provides daily intelligence for leaders in biotech, medtech, and pharma. This daily brief is intended for context, not investment recommendation.
